Description:
Capecitabine is an oral chemotherapy medication that is primarily used in the treatment of various types of cancer, particularly breast cancer and colorectal cancer. It is a prodrug that is converted into its active form, 5-fluorouracil (5-FU), in the body.
Key Information and Uses:
Indications:
Breast Cancer: Capecitabine is used as a treatment for metastatic breast cancer, often in patients who have previously received chemotherapy.
Colorectal Cancer: It is commonly used for the treatment of metastatic colorectal cancer, either alone or in combination with other chemotherapy agents.
Other Cancers: Capecitabine may also be used in the treatment of other cancers, such as gastric cancer and pancreatic cancer, depending on specific clinical circumstances.
Mechanism of Action:
Capecitabine is converted to 5-fluorouracil (5-FU) in the liver and tumor tissues. 5-FU interferes with the synthesis of DNA and RNA by inhibiting thymidylate synthase, which is crucial for DNA replication. This action leads to the inhibition of cancer cell growth and proliferation.
Administration:
Capecitabine is taken orally, usually in the form of tablets, and is typically administered in cycles. The dosage and duration of treatment depend on the specific cancer being treated, the patient’s overall health, and their response to therapy.
Side Effects:
Common side effects of capecitabine include nausea, vomiting, diarrhea, hand-foot syndrome (redness, swelling, and pain on the palms of the hands and soles of the feet), fatigue, and changes in blood counts. Patients should be monitored for these effects, and dose adjustments may be necessary based on tolerance.
Clinical Trials:
Capecitabine has been extensively studied in clinical trials, demonstrating its effectiveness in improving survival rates and quality of life for patients with advanced breast and colorectal cancers.
Approval:
Capecitabine was approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast and colorectal cancers and has become a standard treatment option in oncology.
. Food and Drug Administration (FDA) for the treatment of type 2 diabetes and has been widely used as part of diabetes management regimens.
China
